View live charts, options flow & technicals for Amgen Inc. →
Open Dashboard
Amgen Inc. (AMGN) is a healthcare company in the drug manufacturers - general industry with $38.09B in trailing revenue trading at a 25.5× trailing P/E — analyst consensus: hold.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Key Statistics
Market Cap
$219.55B
Revenue (TTM)
$38.09B
EPS (TTM)
$15.92
EPS (Fwd est.)
$24.43
Employees
31,500
Trailing P/E
25.51
Forward P/E
16.62
PEG Ratio
2.48
Price / Sales
5.76
Price / Book
18.78
EV / EBITDA
15.22
Beta (5Y)
0.43
Analyst Consensus
Consensus
Hold
Analyst Price Target
-4.2% downside
Target: $389.22
Annual Revenue & Net Income
RevenueNet Income
'22
$26.32B
$6.55B
'23
$28.19B
$6.72B
'24
$33.42B
$4.09B
'25
$36.75B
$7.71B
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$6.29
$5.62
Beat (+12.0%)
Apr 2026
$5.15
$4.77
Beat (+8.0%)
Feb 2026
$5.29
$4.73
Beat (+11.9%)
Nov 2025
$5.64
$5.01
Beat (+12.5%)
Next Earnings Report
Amgen Inc. is next expected to report earnings on 03 Nov 2026.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wit…
What is AMGN's market cap?
Amgen Inc. has a market capitalization of approximately $219.55B.
What is AMGN's P/E ratio?
Amgen Inc. trades at a trailing P/E ratio of 25.5x and a forward P/E of 16.6x, which is above the broad market average of ~25x.
How much revenue does AMGN generate?
Amgen Inc. generated $38.09B in trailing 12-month revenue.
What do analysts say about AMGN?
The analyst consensus rating for Amgen Inc. is hold, with a mean price target of $389.22. That implies -4.2% upside from the current price.
When does AMGN report earnings?
Amgen Inc. is next scheduled to report earnings on 03 Nov 2026.
Does AMGN pay a dividend?
Yes. Amgen Inc. pays a dividend with a current yield of 2.46%, at an annual rate of $10.08 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Amgen Inc. on Apsis Markets.
